EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma
11. Dezember 2024 07:00 ET
|
Immunocore Holdings plc
ATOM is the only active Phase 3 trial for adjuvant treatment of uveal melanoma The trial will assess whether adjuvant treatment with tebentafusp can decrease the risk of relapse, compared to...
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
03. Dezember 2024 01:00 ET
|
Immunocore Holdings plc
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma (OXFORDSHIRE, England &...
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
01. Juni 2024 08:00 ET
|
Immunocore Holdings plc
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response Data were...
Immunocore announces upcoming presentation and posters at ASCO 2024
24. April 2024 10:00 ET
|
Immunocore Holdings plc
Immunocore announces upcoming presentation and posters at ASCO 2024 Phase 1 expansion data in immune checkpoints pre-treated cutaneous melanoma for brenetafusp (IMC-F106C targeting PRAME) to be...
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
05. Januar 2024 07:00 ET
|
Immunocore Holdings Limited
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation Increasing commercial access to KIMMTRAK (tebentafusp-tebn)...
Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update
07. November 2023 07:00 ET
|
Immunocore Holdings Limited
Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of £49.7 million ($60.7 million) in Q3 2023, maintaining strong momentum in major...
Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial
21. Oktober 2023 08:45 ET
|
Immunocore Holdings Limited
Data published in New England Journal of Medicine and presented as a late breaking abstract in mini oral session at ESMO Congress 2023 KIMMTRAK demonstrated long-term survival benefit in HLA-A*02:01...
Immunocore announces upcoming presentation and posters at ESMO 2023
06. Oktober 2023 07:01 ET
|
Immunocore Holdings Limited
Immunocore announces upcoming presentation and posters at ESMO 2023 Long-term survival data for KIMMTRAK in previously untreated patients with metastatic uveal melanoma to be presented as a...
Immunocore to report second quarter 2023 financial results and host call on August 10, 2023
03. August 2023 08:00 ET
|
Immunocore Holdings Limited
Immunocore to report second quarter 2023 financial results and host call on August 10, 2023 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 03 August 2023) Immunocore...
Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
03. Juni 2023 07:00 ET
|
Immunocore Holdings Limited
Early on-treatment ctDNA reduction in stable disease patients treated with KIMMTRAK was associated with longer overall survival (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, 3...